Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
Keyword(s):
Phase 2
◽
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 93
(4)
◽
pp. 757-764
◽